SCHEMBL30452345

SCHEMBL30452345

O=C(Cl)Cc1ccc(Cl)cc1Br

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PYCR1 P32322 1/20 0.41
PPARA Q07869 1/20 0.40
IDO1 P14902 3/20 0.38
FLT1 P17948 1/20 0.37
FLT4 P35916 1/20 0.37
KDR P35968 1/20 0.37
NPC1 O15118 2/20 0.37
GRIK1 P39086 1/20 0.37
KEAP1 Q14145 1/20 0.36
NFE2L2 Q16236 1/20 0.36
TP53 P04637 1/20 0.36
MDM2 Q00987 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
HSP90AA1 P07900 2/20 0.35
MAPT P10636 2/20 0.35
HIF1A Q16665 2/20 0.35
MEN1 O00255 1/20 0.35
SLC22A1 O15245 1/20 0.35
USP2 O75604 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9596857 1.00 PYCR1 (0.41) PYCR1PPARAIDO1FLT1FLT4
SCHEMBL25253767 0.93 KEAP1 (0.45) PYCR1PPARAGRIK1KEAP1NFE2L2
SCHEMBL4706380 0.87 SIRT1 (0.45) PYCR1PPARASMN1; SMN2HSP90AA1MAPT
SCHEMBL30452038 0.85 KEAP1 (0.50) PYCR1PPARAGRIK1KEAP1NFE2L2
SCHEMBL4047837 0.85 KEAP1 (0.50) PYCR1PPARAGRIK1KEAP1NFE2L2
SCHEMBL27033373 0.85 MAPT (0.39) PPARAIDO1KEAP1NFE2L2TP53
SCHEMBL22122719 0.83 PYCR1 (0.44) PYCR1PPARAIDO1FLT1FLT4
SCHEMBL30485967 0.83 PYCR1 (0.44) PYCR1PPARAIDO1FLT1FLT4
SCHEMBL22124351 0.81 PYCR1 (0.40) PYCR1PPARAIDO1FLT1FLT4
SCHEMBL22123456 0.80 PYCR1 (0.42) PYCR1PPARAIDO1FLT1FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 US disclosed
CN-116947903-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-10-27 CN disclosed
CN-116261564-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-06-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH PYCR1 3558/4885PPARA 3923/4885IDO1 1123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.